Table 2.

Univariate analyses of prognostic factors correlated with PFS and OS

Variables	Progression-free survival				Over survival
	Training cohort		Validation cohort		Training cohort		Validation cohort
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age (y) ≥53/<53	1.251 (0.73 to 2.15)	0.415	1.55 (00.93 to 2.59)	0.091	1.57 (0.89 to 2.80)	0.122	1.58 (0.92 to 2.71)	0.096
Gender male/female	0.97 (0.56 to 1.70)	0.926	0.99 (0.57 to 1.75)	0.986	1.03 (0.58 to 1.82)	0.928	1.19 (90.67 to 2.11)	0.561
Necrosis present/absent	2.18 (1.28 to 3.74)	0.004	2.22 (1.30 to 3.77)	0.003	1.96 (1.12 to 3.43)	0.018	2.42 (1.39 to 4.20)	0.002
MVI present/absent	2.97 (1.62 to 5.46)	< 0.001	3.46 (1.98 to 6.07)	< 0.001	2.15 (1.10 to 4.20)	0.024	3.43 (1.90 to 6.18)	< 0.001
Fuhrman grade high/low	3.97 (2.30 to 6.85)	< 0.001	3.45 (2.06 to 5.77)	< 0.001	3.74 (2.13 to 6.57)	< 0.001	3.49 (2.03 to 6.02)	< 0.001
TNM stage high/low	7.92 (4.46 to 14.08)	< 0.001	3.77 (2.27 to 6.25)	< 0.001	7.14 (3.98 to 12.83)	< 0.001	3.93 (2.30 to 6.19)	< 0.001
HHLA2 positive/negative	3.23 (1.90 to 5.50)	< 0.001	2.17 (1.30 to 3.62)	0.003	3.98 (2.15 to 7.37)	< 0.001	3.19 (1.82 to 5.58)	< 0.001
PD-L1 positive/negative	3.26 (1.91 to 5.55)	< 0.001	2.77 (1.66 to 4.61)	< 0.001	3.02 (1.73 to 5.24)	< 0.001	2.92 (1.71 to 4.99)	< 0.001

*P values <0.05 in bold are statistically significant.

HHLA2, human endogenous retrovirus-H long terminal repeat-associating protein 2; MVI, microvascular invasion; OS, overall survival; PD-L1, programmed death 1 ligand 1; PFS, progression-free survival.